T cells engineered with a T cell receptor against the prostate antigen TARP specifically kill HLA-A2+ prostate and breast cancer cells

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 39, 2012, Pages 15877-15881

  Hillerdal, Victoria ^a   Nilsson, Berith ^a   Carlsson, Björn ^a   Eriksson, Fredrik ^a   Essand, Magnus ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Genetic engineering; T cell receptor transfer

Indexed keywords

GAMMA INTERFERON; HLA A2 ANTIGEN; LENTIVIRUS VECTOR; PROSTATE ANTIGEN; PROTEIN; T CELL RECEPTOR GAMMA CHAIN ALTERNATE READING FRAME PROTEIN; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; CYTOTOXICITY; GENETIC ENGINEERING; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; INTERFERON PRODUCTION; MALE; MOLECULAR CLONING; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; T LYMPHOCYTE;

ADOPTIVE TRANSFER; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CELL ENGINEERING; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION; HLA-A2 ANTIGEN; HUMANS; IMMUNITY, CELLULAR; MALE; NUCLEAR PROTEINS; PROSTATIC NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 84866850033     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1209042109     Document Type: Article

References (21)

1. Kalos M, et al. (2011) T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3:95ra73.
2. Morgan RA, et al. (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314:126-129. (Pubitemid 44547756)
3. Porter DL, Levine BL, Kalos M, Bagg A, June CH (2011) Chimeric antigen receptormodified T cells in chronic lymphoid leukemia. N Engl J Med 365:725-733.
4. Gong MC, et al. (1999) Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia 1:123-127.
5. Gade TP, et al. (2005) Targeted elimination of prostate cancer by genetically directed human T lymphocytes. Cancer Res 65:9080-9088. (Pubitemid 41377401)
6. Morgenroth A, et al. (2007) Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells. Prostate 67:1121-1131. (Pubitemid 46983341)
7. Essand M, et al. (1999) High expression of a specific T-cell receptor gamma transcript in epithelial cells of the prostate. Proc Natl Acad Sci USA 96:9287-9292. (Pubitemid 29374747)
8. Wolfgang CD, Essand M, Vincent JJ, Lee B, Pastan I (2000) TARP: A nuclear protein expressed in prostate and breast cancer cells derived from an alternate reading frame of the T cell receptor gamma chain locus. Proc Natl Acad Sci USA 97:9437-9442. (Pubitemid 30650793)
9. Carlsson B, Tötterman TH, Essand M (2004) Generation of cytotoxic T lymphocytes specific for the prostate and breast tissue antigen TARP. Prostate 61:161-170. (Pubitemid 39244703)
10. Oh S, et al. (2004) Human CTLs to wild-type and enhanced epitopes of a novel prostate and breast tumor-associated protein, TARP, lyse human breast cancer cells. Cancer Res 64:2610-2618. (Pubitemid 38523919)
11. Kobayashi H, et al. (2005) Recognition of prostate and breast tumor cells by helper T lymphocytes specific for a prostate and breast tumor-associated antigen, TARP. Clin Cancer Res 11:3869-3878. (Pubitemid 40685608)
12. Epel M, et al. (2008) Targeting TARP, a novel breast and prostate tumor-associated antigen, with T cell receptor-like human recombinant antibodies. Eur J Immunol 38: 1706-1720.
13. Nguyen MC, et al. (2010) Antibody responses to galectin-8, TARP and TRAP1 in prostate cancer patients treated with a GM-CSF-secreting cellular immunotherapy. Cancer Immunol Immunother 59:1313-1323.
14. Forsberg O, et al. (2009) High frequency of prostate antigen-directed T cells in cancer patients compared to healthy age-matched individuals. Prostate 69:70-81.
15. Carlsson B, Forsberg O, Bengtsson M, Tötterman TH, EssandM(2007) Characterization of human prostate and breast cancer cell lines for experimental T cell-based immunotherapy. Prostate 67:389-395. (Pubitemid 46341079)
16. Sanda MG, et al. (1995) Molecular characterization of defective antigen processing in human prostate cancer. J Natl Cancer Inst 87:280-285.
17. Agarwal N, Padmanabh S, Vogelzang NJ (2012) Development of novel immune interventions for prostate cancer. Clin Genitourin Cancer 10:84-92.
18. Cohen CJ, Zhao Y, Zheng Z, Rosenberg SA, Morgan RA (2006) Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res 66:8878-8886. (Pubitemid 44449206)
19. Kozak M (1984) Compilation and analysis of sequences upstream from the translational start site in eukaryotic mRNAs. Nucleic Acids Res 12:857-872.
20. Szymczak AL, et al. (2004) Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. Nat Biotechnol 22:589-594. (Pubitemid 38585911)
21. Carlsson B, Cheng WS, Tötterman TH, Essand M (2003) Ex vivo stimulation of cytomegalovirus (CMV)-specific T cells using CMV pp65-modified dendritic cells as stimulators. Br J Haematol 121:428-438. (Pubitemid 36628334)